

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2014/152635 A9

(43) International Publication Date
25 September 2014 (25.09.2014)

(51) International Patent Classification:

A61K 31/454 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4985 (2006.01) *A61P 31/22* (2006.01)
A61K 31/7056 (2006.01)

(21) International Application Number:

PCT/US2014/027556

(22) International Filing Date:

14 March 2014 (14.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/783,437 14 March 2013 (14.03.2013) US

(71) Applicant: **ABBVIE INC.** [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US).

(72) Inventors: **BERNSTEIN, Barry M.**; 10829 Wyngate Trace, Mequon, Wisconsin 53092 (US). **DUTTA, Sandeep**; 1 Charlestowne Court, Lincolnshire, Illinois 60069 (US). **LIU, Wei**; 1287 Derby Lane, Mundelein, Illinois 60060 (US). **PODSADECKI, Thomas J.**; 670 Alice Drive, Northbrook, Illinois 60062 (US). **CAMPBELL, Andrew L.**; 520 Stablewood Lane, Lake Forest, Illinois 60045 (US). **MENON, Rajeev M.**; 81 Pinyon Pine

Court, Buffalo Grove, Illinois 60089 (US). **LIN, Chih-Wei**; 323 Aspen Pointe Road, Vernon Hills, Illinois 60061 (US). **WANG, Tianli**; 29537 N. Waukegan Road, Apt. 302, Lake Bluff, Illinois 60044 (US). **AWNI, Walid M.**; 14105 Edgewater Court, Green Oaks, Illinois 60048 (US).

(74) Agents: **ZHANG, Xu** et al.; AbbVie Inc. 1 North Waukegan Road AP34-2/V377, North Chicago, Illinois 60064 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS




Figure 1

(57) Abstract: The present invention features interferon -free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 and (b) Compound 2 or a pharmaceutically acceptable salt thereof as disclosed in the description.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

11 December 2014

(15) Information about Correction:

see Notice of 11 December 2014